

2026-2031 Global Monoclonal Antibodies for Non-small Cell Lung Cancer Outlook Market Size, Share & Trends Analysis Report By Player, Type, Application and Region

<https://marketpublishers.com/r/M7D753AF3DC7EN.html>

Date: August 2026

Pages: 130

Price: US\$ 3,150.00 (Single User License)

ID: M7D753AF3DC7EN

Abstracts

HNY Research projects that the Monoclonal Antibodies for Non-small Cell Lung Cancer market size will grow from 11855.2 Million USD in 2025 to 25051.2 Million USD by 2031, at an estimated CAGR of 13.28%. The base year considered for the study is 2025, and the market size is projected from 2026 to 2031.

For 2025 regional market size, the North America market size was 2325.99 Million USD, the Europe market size was 2112.6 Million USD, and the Asia market size was 2178.99 Million USD.

This report presents a detailed and holistic analysis of the global Monoclonal Antibodies for Non-small Cell Lung Cancer market. It integrates quantitative data with qualitative insights to equip readers with the necessary information for strategic planning, competitive assessment, market positioning, and data-driven decision-making.

All market sizes, estimates, and forecasts are expressed in terms of output/shipments and revenue. With 2025 serving as the base year, the report provides historical context from 2020. and projections up to 2031. It includes a complete segmentation of the global market, along with regional market sizes analyzed by type, application, and key industry participants.

Further enriching the analysis, the report outlines the competitive environment, offering profiles of prominent players and their market standings. It also explores key technological advancements and recent developments in product offerings.

Ultimately, this report serves as a vital resource for Monoclonal Antibodies for Non-small Cell Lung Cancer manufacturers, prospective entrants, and other stakeholders within the industry value chain. It supplies comprehensive data on revenues, production, and average pricing for the overall market and its sub-segments, detailed by company, product type, application, and geographic region.

By Market Players:

Roche Holding AG
Bristol Myers Squibb Co.
Elea Spa
Eli Lilly & Co.
Merck & Co., Inc.
AstraZeneca PLC
Regeneron Pharmaceuticals, Inc.
Henlius Biopharma Co., Ltd
Jiangsu Hengrui Medicine Co., Ltd
Innovent Biologics Co., Ltd
Junshi Biosciences Co., Ltd
BeiGene, Ltd
Akeso, Inc

By Type

5 mg/mL
10 mg/mL
25 mg/mL
50 mg/mL

By Application

Hospitals
Clinic
Others

By Regions/Countries:

North America
East Asia
Europe
South Asia
Southeast Asia
Middle East

Africa
Oceania
South America

Points Covered in The Report

The points that are discussed within the report are the major market players that are involved in the market such as market players, raw material suppliers, equipment suppliers, end users, traders, distributors and etc.

The complete profile of the companies is mentioned. And the capacity, production, price, revenue, cost, gross, gross margin, sales volume, sales revenue, consumption, growth rate, import, export, supply, future strategies, and the technological developments that they are making are also included within the report. This report analyzed 12 years data history and forecast.

The growth factors of the market is discussed in detail wherein the different end users of the market are explained in detail.

Data and information by market player, by region, by type, by application and etc, and custom research can be added according to specific requirements.

The report contains the SWOT analysis of the market. Finally, the report contains the conclusion part where the opinions of the industrial experts are included.

Key Reasons to Purchase

To gain insightful analyses of the market and have comprehensive understanding of the global market and its commercial landscape.

Assess the production processes, major issues, and solutions to mitigate the development risk.

To understand the most affecting driving and restraining forces in the market and its impact in the global market.

Learn about the market strategies that are being adopted by leading respective

organizations.

To understand the future outlook and prospects for the market.

Besides the standard structure reports, we also provide custom research according to specific requirements.

Contents

1 REPORT OVERVIEW

- 1.1 Study Scope
- 1.2 Key Market Segments
- 1.3 Global Market Size by Player 2020-2025
- 1.4 Global Market Size by Type in 2026-2031
 - 1.4.1 Global Market Size by Type in 2026-2031
 - 1.4.2 5 mg/mL
 - 1.4.3 10 mg/mL
 - 1.4.4 25 mg/mL
 - 1.4.5 50 mg/mL
- 1.5 Global Market Size by Application in 2026-2031
 - 1.5.1 Global Market Size by Application in 2026-2031
 - 1.5.2 Hospitals
 - 1.5.3 Clinic
 - 1.5.4 Others
- 1.6 Global Market Size by Region 2026-2031
 - 1.6.1 Global Market Size Outlook 2026-2031
 - 1.6.2 North America
 - 1.6.3 East Asia
 - 1.6.4 Europe
 - 1.6.5 South Asia
 - 1.6.6 Southeast Asia
 - 1.6.7 Middle East
 - 1.6.8 Africa
 - 1.6.9 Oceania
 - 1.6.10 South America
 - 1.6.11 Rest of the World

2 MANUFACTURING COST STRUCTURE ANALYSIS 2026

- 2.1 Manufacturing Cost Structure Analysis of Monoclonal Antibodies for Non-small Cell Lung Cancer 2026
- 2.2 Industry Chain Structure Analysis of Monoclonal Antibodies for Non-small Cell Lung Cancer 2026

3 MARKET COMPETITION ANALYSIS BY PLAYERS 2020-2025

3.1 Global Monoclonal Antibodies for Non-small Cell Lung Cancer Production Capacity by Players 2020-2025

3.2 Global Monoclonal Antibodies for Non-small Cell Lung Cancer Production Revenue by Players 2020-2025

3.3 Global Monoclonal Antibodies for Non-small Cell Lung Cancer Ex-Factory Price by Players 2020-2025

4 MARKET COMPETITION ANALYSIS BY REGION 2020-2025

4.1 Global Monoclonal Antibodies for Non-small Cell Lung Cancer Production by Region 2020-2025

4.1.1 Global Monoclonal Antibodies for Non-small Cell Lung Cancer Production Volume by Region 2020-2025

4.1.2 Global Monoclonal Antibodies for Non-small Cell Lung Cancer Production Revenue by Region 2020-2025

4.2 Global Monoclonal Antibodies for Non-small Cell Lung Cancer Consumption Volume by Region 2020-2025

4.3 North America Monoclonal Antibodies for Non-small Cell Lung Cancer Market Competition Analysis 2020-2025

4.3.1 North America Monoclonal Antibodies for Non-small Cell Lung Cancer Production Volume Analysis 2020-2025

4.3.2 North America Monoclonal Antibodies for Non-small Cell Lung Cancer Production Revenue Analysis 2020-2025

4.3.3 North America Monoclonal Antibodies for Non-small Cell Lung Cancer Sales Volume by Key Players 2020-2025

4.3.4 North America Monoclonal Antibodies for Non-small Cell Lung Cancer Production, Consumption, Import and Export 2020-2025

4.4 East Asia Monoclonal Antibodies for Non-small Cell Lung Cancer Market Competition Analysis 2020-2025

4.4.1 East Asia Monoclonal Antibodies for Non-small Cell Lung Cancer Production Volume Analysis 2020-2025

4.4.2 East Asia Monoclonal Antibodies for Non-small Cell Lung Cancer Production Revenue Analysis 2020-2025

4.4.3 East Asia Monoclonal Antibodies for Non-small Cell Lung Cancer Sales Volume by Key Players 2020-2025

4.4.4 East Asia Monoclonal Antibodies for Non-small Cell Lung Cancer Production, Consumption, Import and Export 2020-2025

4.5 Europe Monoclonal Antibodies for Non-small Cell Lung Cancer Market Competition

Analysis 2020-2025

4.5.1 Europe Monoclonal Antibodies for Non-small Cell Lung Cancer Production

Volume Analysis 2020-2025

4.5.2 Europe Monoclonal Antibodies for Non-small Cell Lung Cancer Production

Revenue Analysis 2020-2025

4.5.3 Europe Monoclonal Antibodies for Non-small Cell Lung Cancer Sales Volume by Key Players 2020-2025

4.5.4 Europe Monoclonal Antibodies for Non-small Cell Lung Cancer Production, Consumption, Import and Export 2020-2025

4.6 South Asia Monoclonal Antibodies for Non-small Cell Lung Cancer Market Competition Analysis 2020-2025

4.6.1 South Asia Monoclonal Antibodies for Non-small Cell Lung Cancer Production Volume Analysis 2020-2025

4.6.2 South Asia Monoclonal Antibodies for Non-small Cell Lung Cancer Production Revenue Analysis 2020-2025

4.6.3 South Asia Monoclonal Antibodies for Non-small Cell Lung Cancer Sales Volume by Key Players 2020-2025

4.6.4 South Asia Monoclonal Antibodies for Non-small Cell Lung Cancer Production, Consumption, Import and Export 2020-2025

4.7 Southeast Asia Monoclonal Antibodies for Non-small Cell Lung Cancer Market Competition Analysis 2020-2025

4.7.1 Southeast Asia Monoclonal Antibodies for Non-small Cell Lung Cancer Production Volume Analysis 2020-2025

4.7.2 Southeast Asia Monoclonal Antibodies for Non-small Cell Lung Cancer Production Revenue Analysis 2020-2025

4.7.3 Southeast Asia Monoclonal Antibodies for Non-small Cell Lung Cancer Sales Volume by Key Players 2020-2025

4.7.4 Southeast Asia Monoclonal Antibodies for Non-small Cell Lung Cancer Production, Consumption, Import and Export 2020-2025

4.8 Middle East Monoclonal Antibodies for Non-small Cell Lung Cancer Market Competition Analysis 2020-2025

4.8.1 Middle East Monoclonal Antibodies for Non-small Cell Lung Cancer Production Volume Analysis 2020-2025

4.8.2 Middle East Monoclonal Antibodies for Non-small Cell Lung Cancer Production Revenue Analysis 2020-2025

4.8.3 Middle East Monoclonal Antibodies for Non-small Cell Lung Cancer Sales Volume by Key Players 2020-2025

4.8.4 Middle East Monoclonal Antibodies for Non-small Cell Lung Cancer Production, Consumption, Import and Export 2020-2025

4.9 Africa Monoclonal Antibodies for Non-small Cell Lung Cancer Market Competition Analysis 2020-2025

4.9.1 Africa Monoclonal Antibodies for Non-small Cell Lung Cancer Production Volume Analysis 2020-2025

4.9.2 Africa Monoclonal Antibodies for Non-small Cell Lung Cancer Production Revenue Analysis 2020-2025

4.9.3 Africa Monoclonal Antibodies for Non-small Cell Lung Cancer Sales Volume by Key Players 2020-2025

4.9.4 Africa Monoclonal Antibodies for Non-small Cell Lung Cancer Production, Consumption, Import and Export 2020-2025

4.10 Oceania Monoclonal Antibodies for Non-small Cell Lung Cancer Market Competition Analysis 2020-2025

4.10.1 Oceania Monoclonal Antibodies for Non-small Cell Lung Cancer Production Volume Analysis 2020-2025

4.10.2 Oceania Monoclonal Antibodies for Non-small Cell Lung Cancer Production Revenue Analysis 2020-2025

4.10.3 Oceania Monoclonal Antibodies for Non-small Cell Lung Cancer Sales Volume by Key Players 2020-2025

4.10.4 Oceania Monoclonal Antibodies for Non-small Cell Lung Cancer Production, Consumption, Import and Export 2020-2025

4.11 South America Monoclonal Antibodies for Non-small Cell Lung Cancer Market Competition Analysis 2020-2025

4.11.1 South America Monoclonal Antibodies for Non-small Cell Lung Cancer Production Volume Analysis 2020-2025

4.11.2 South America Monoclonal Antibodies for Non-small Cell Lung Cancer Production Revenue Analysis 2020-2025

4.11.3 South America Monoclonal Antibodies for Non-small Cell Lung Cancer Sales Volume by Key Players 2020-2025

4.11.4 South America Monoclonal Antibodies for Non-small Cell Lung Cancer Production, Consumption, Import and Export 2020-2025

5 MARKET COMPETITION ANALYSIS BY TYPE (SALES VIEW) 2020-2031

5.1 Global Monoclonal Antibodies for Non-small Cell Lung Cancer Historic Market Size by Type in 2020-2025

5.2 Global Monoclonal Antibodies for Non-small Cell Lung Cancer Forecasted Market Size by Type in 2026-2031

6 MARKET COMPETITION ANALYSIS BY APPLICATION (CONSUMPTION VIEW)

2020-2031

6.1 Global Monoclonal Antibodies for Non-small Cell Lung Cancer Historic Market Size by Application in 2020-2025

6.2 Global Monoclonal Antibodies for Non-small Cell Lung Cancer Forecasted Market Size by Application in 2026-2031

7 LEADING COMPANY PROFILES AND KEY FIGURES IN MONOCLONAL ANTIBODIES FOR NON-SMALL CELL LUNG CANCER BUSINESS 2020-2025

7.1 Roche Holding AG

7.1.1 Roche Holding AG Company Profile

7.1.2 Roche Holding AG Monoclonal Antibodies for Non-small Cell Lung Cancer Product Specification

7.1.3 Roche Holding AG Monoclonal Antibodies for Non-small Cell Lung Cancer Production Capacity, Revenue, Price and Gross Margin 2020-2025

7.2 Bristol Myers Squibb Co.

7.2.1 Bristol Myers Squibb Co. Company Profile

7.2.2 Bristol Myers Squibb Co. Monoclonal Antibodies for Non-small Cell Lung Cancer Product Specification

7.2.3 Bristol Myers Squibb Co. Monoclonal Antibodies for Non-small Cell Lung Cancer Production Capacity, Revenue, Price and Gross Margin 2020-2025

7.3 Elea Spa

7.3.1 Elea Spa Company Profile

7.3.2 Elea Spa Monoclonal Antibodies for Non-small Cell Lung Cancer Product Specification

7.3.3 Elea Spa Monoclonal Antibodies for Non-small Cell Lung Cancer Production Capacity, Revenue, Price and Gross Margin 2020-2025

7.4 Eli Lilly & Co.

7.4.1 Eli Lilly & Co. Company Profile

7.4.2 Eli Lilly & Co. Monoclonal Antibodies for Non-small Cell Lung Cancer Product Specification

7.4.3 Eli Lilly & Co. Monoclonal Antibodies for Non-small Cell Lung Cancer Production Capacity, Revenue, Price and Gross Margin 2020-2025

7.5 Merck & Co., Inc.

7.5.1 Merck & Co., Inc. Company Profile

7.5.2 Merck & Co., Inc. Monoclonal Antibodies for Non-small Cell Lung Cancer Product Specification

7.5.3 Merck & Co., Inc. Monoclonal Antibodies for Non-small Cell Lung Cancer

Production Capacity, Revenue, Price and Gross Margin 2020-2025

7.6 AstraZeneca PLC

7.6.1 AstraZeneca PLC Company Profile

7.6.2 AstraZeneca PLC Monoclonal Antibodies for Non-small Cell Lung Cancer

Product Specification

7.6.3 AstraZeneca PLC Monoclonal Antibodies for Non-small Cell Lung Cancer

Production Capacity, Revenue, Price and Gross Margin 2020-2025

7.7 Regeneron Pharmaceuticals, Inc.

7.7.1 Regeneron Pharmaceuticals, Inc. Company Profile

7.7.2 Regeneron Pharmaceuticals, Inc. Monoclonal Antibodies for Non-small Cell Lung Cancer Product Specification

7.7.3 Regeneron Pharmaceuticals, Inc. Monoclonal Antibodies for Non-small Cell Lung Cancer Production Capacity, Revenue, Price and Gross Margin 2020-2025

7.8 Henlius Biopharma Co., Ltd

7.8.1 Henlius Biopharma Co., Ltd Company Profile

7.8.2 Henlius Biopharma Co., Ltd Monoclonal Antibodies for Non-small Cell Lung Cancer Product Specification

7.8.3 Henlius Biopharma Co., Ltd Monoclonal Antibodies for Non-small Cell Lung Cancer Production Capacity, Revenue, Price and Gross Margin 2020-2025

7.9 Jiangsu Hengrui Medicine Co., Ltd

7.9.1 Jiangsu Hengrui Medicine Co., Ltd Company Profile

7.9.2 Jiangsu Hengrui Medicine Co., Ltd Monoclonal Antibodies for Non-small Cell Lung Cancer Product Specification

7.9.3 Jiangsu Hengrui Medicine Co., Ltd Monoclonal Antibodies for Non-small Cell Lung Cancer Production Capacity, Revenue, Price and Gross Margin 2020-2025

7.10 Innovent Biologics Co., Ltd

7.10.1 Innovent Biologics Co., Ltd Company Profile

7.10.2 Innovent Biologics Co., Ltd Monoclonal Antibodies for Non-small Cell Lung Cancer Product Specification

7.10.3 Innovent Biologics Co., Ltd Monoclonal Antibodies for Non-small Cell Lung Cancer Production Capacity, Revenue, Price and Gross Margin 2020-2025

7.11 Junshi Biosciences Co., Ltd

7.11.1 Junshi Biosciences Co., Ltd Company Profile

7.11.2 Junshi Biosciences Co., Ltd Monoclonal Antibodies for Non-small Cell Lung Cancer Product Specification

7.11.3 Junshi Biosciences Co., Ltd Monoclonal Antibodies for Non-small Cell Lung Cancer Production Capacity, Revenue, Price and Gross Margin 2020-2025

7.12 BeiGene, Ltd

7.12.1 BeiGene, Ltd Company Profile

7.12.2 BeiGene, Ltd Monoclonal Antibodies for Non-small Cell Lung Cancer Product Specification

7.12.3 BeiGene, Ltd Monoclonal Antibodies for Non-small Cell Lung Cancer Production Capacity, Revenue, Price and Gross Margin 2020-2025

7.13 Akeso, Inc

7.13.1 Akeso, Inc Company Profile

7.13.2 Akeso, Inc Monoclonal Antibodies for Non-small Cell Lung Cancer Product Specification

7.13.3 Akeso, Inc Monoclonal Antibodies for Non-small Cell Lung Cancer Production Capacity, Revenue, Price and Gross Margin 2020-2025

8 MARKET FORECAST ANALYSIS ON PRODUCTION AND SUPPLY BY REGION 2026-2031

8.1 Global Forecasted Production Capacity of Monoclonal Antibodies for Non-small Cell Lung Cancer 2026-2031

8.2 Global Forecasted Production Revenue of Monoclonal Antibodies for Non-small Cell Lung Cancer 2026-2031

8.3 Global Forecasted Production Volume of Monoclonal Antibodies for Non-small Cell Lung Cancer by Region 2026-2031

8.3.1 North America Forecasted Production of Monoclonal Antibodies for Non-small Cell Lung Cancer 2026-2031

8.3.2 East Asia Forecasted Production of Monoclonal Antibodies for Non-small Cell Lung Cancer 2026-2031

8.3.3 Europe Forecasted Production of Monoclonal Antibodies for Non-small Cell Lung Cancer 2026-2031

8.3.4 South Asia Forecasted Production of Monoclonal Antibodies for Non-small Cell Lung Cancer 2026-2031

8.3.5 Southeast Asia Forecasted Production of Monoclonal Antibodies for Non-small Cell Lung Cancer 2026-2031

8.3.6 Middle East Forecasted Production of Monoclonal Antibodies for Non-small Cell Lung Cancer 2026-2031

8.3.7 Africa Forecasted Production of Monoclonal Antibodies for Non-small Cell Lung Cancer 2026-2031

8.3.8 Oceania Forecasted Production of Monoclonal Antibodies for Non-small Cell Lung Cancer 2026-2031

8.3.9 South America Forecasted Production of Monoclonal Antibodies for Non-small Cell Lung Cancer 2026-2031

8.3.10 Rest of the World Forecasted Production of Monoclonal Antibodies for Non-

small Cell Lung Cancer 2026-2031

8.4 Global Forecasted Sales by Type and Consumption by Application in 2026-2031

8.4.1 Global Forecasted Sales Volume, Sales Revenue and Sales Price by Type in 2026-2031

8.4.2 Global Forecasted Consumption Volume and Consumption Value by Application in 2026-2031

9 MARKET FORECAST ANALYSIS ON CONSUMPTION AND DEMAND BY REGION 2026-2031

9.1 North America Forecasted Consumption of Monoclonal Antibodies for Non-small Cell Lung Cancer by Country

9.2 East Asia Forecasted Consumption of Monoclonal Antibodies for Non-small Cell Lung Cancer by Country

9.3 Europe Market Forecasted Consumption of Monoclonal Antibodies for Non-small Cell Lung Cancer by Country

9.4 South Asia Forecasted Consumption of Monoclonal Antibodies for Non-small Cell Lung Cancer by Country

9.5 Southeast Asia Forecasted Consumption of Monoclonal Antibodies for Non-small Cell Lung Cancer by Country

9.6 Middle East Forecasted Consumption of Monoclonal Antibodies for Non-small Cell Lung Cancer by Country

9.7 Africa Forecasted Consumption of Monoclonal Antibodies for Non-small Cell Lung Cancer by Country

9.8 Oceania Forecasted Consumption of Monoclonal Antibodies for Non-small Cell Lung Cancer by Country

9.9 South America Forecasted Consumption of Monoclonal Antibodies for Non-small Cell Lung Cancer by Country

9.10 Rest of the World Forecasted Consumption of Monoclonal Antibodies for Non-small Cell Lung Cancer by Country

10 MARKETING CHANNEL, DISTRIBUTORS AND CUSTOMERS ANALYSIS

10.1 Marketing Channel

10.1.1 Direct Channels

10.1.2 Indirect Channels

11 MARKET DYNAMICS ANALYSIS

- 11.1 Market Trends
- 11.2 Opportunities and Drivers
- 11.3 Challenges
- 11.4 Porter's Five Forces Analysis

12 CONCLUSION

13 APPENDIX

- 13.1 Methodology/Research Approach
 - 13.1.1 Research Programs/Design
 - 13.1.2 Market Size Estimation
 - 13.1.3 Market Breakdown and Data Triangulation
 - 13.2 Data Source
 - 13.2.1 Secondary Sources
 - 13.2.2 Primary Sources
 - 13.3 Who Trust HNY Research
 - 13.4 Disclaimer
- Research Methodology

List Of Tables

LIST OF TABLES

Table Global Market Size in Production Revenue by Player 2020-2025

Table Global Market Size in Sales Revenue by Type in 2026-2031

Table Global Market Size in Consumption Value by Application in 2026-2031

Table Global Monoclonal Antibodies for Non-small Cell Lung Cancer Production Capacity by Players 2020-2025

Table Global Monoclonal Antibodies for Non-small Cell Lung Cancer Production Volume by Players 2020-2025

Table Global Monoclonal Antibodies for Non-small Cell Lung Cancer Production Volume Market Share by Players 2020-2025

Table Global Monoclonal Antibodies for Non-small Cell Lung Cancer Production Revenue by Players 2020-2025

Table Global Monoclonal Antibodies for Non-small Cell Lung Cancer Production Revenue Share by Players 2020-2025

Table Global Monoclonal Antibodies for Non-small Cell Lung Cancer Ex-Factory Price of Key Players 2020-2025

Table Global Monoclonal Antibodies for Non-small Cell Lung Cancer Production Volume by Region 2020-2025

Table Global Monoclonal Antibodies for Non-small Cell Lung Cancer Production Volume Market Share by Region 2020-2025

Table Global Monoclonal Antibodies for Non-small Cell Lung Cancer Production Revenue by Region 2020-2025

Table Global Monoclonal Antibodies for Non-small Cell Lung Cancer Production Revenue Market Share by Region 2020-2025

Table Global Monoclonal Antibodies for Non-small Cell Lung Cancer Consumption Volume by Region 2020-2025

Table Global Monoclonal Antibodies for Non-small Cell Lung Cancer Consumption Volume Market Share by Region 2020-2025

Table North America Monoclonal Antibodies for Non-small Cell Lung Cancer Sales Volume by Key Players 2020-2025

Table North America Monoclonal Antibodies for Non-small Cell Lung Cancer Production, Consumption, Import and Export 2020-2025

Table East Asia Monoclonal Antibodies for Non-small Cell Lung Cancer Sales Volume by Key Players 2020-2025

Table East Asia Monoclonal Antibodies for Non-small Cell Lung Cancer Production, Consumption, Import and Export 2020-2025

Table Europe Monoclonal Antibodies for Non-small Cell Lung Cancer Sales Volume by Key Players 2020-2025

Table Europe Monoclonal Antibodies for Non-small Cell Lung Cancer Production, Consumption, Import and Export 2020-2025

Table South Asia Monoclonal Antibodies for Non-small Cell Lung Cancer Sales Volume by Key Players 2020-2025

Table South Asia Monoclonal Antibodies for Non-small Cell Lung Cancer Production, Consumption, Import and Export 2020-2025

Table Southeast Asia Monoclonal Antibodies for Non-small Cell Lung Cancer Sales Volume by Key Players 2020-2025

Table Southeast Asia Monoclonal Antibodies for Non-small Cell Lung Cancer Production, Consumption, Import and Export 2020-2025

Table Middle East Monoclonal Antibodies for Non-small Cell Lung Cancer Sales Volume by Key Players 2020-2025

Table Middle East Monoclonal Antibodies for Non-small Cell Lung Cancer Production, Consumption, Import and Export 2020-2025

Table Africa Monoclonal Antibodies for Non-small Cell Lung Cancer Sales Volume by Key Players 2020-2025

Table Africa Monoclonal Antibodies for Non-small Cell Lung Cancer Production, Consumption, Import and Export 2020-2025

Table Oceania Monoclonal Antibodies for Non-small Cell Lung Cancer Sales Volume by Key Players 2020-2025

Table Oceania Monoclonal Antibodies for Non-small Cell Lung Cancer Production, Consumption, Import and Export 2020-2025

Table South America Monoclonal Antibodies for Non-small Cell Lung Cancer Sales Volume by Key Players 2020-2025

Table South America Monoclonal Antibodies for Non-small Cell Lung Cancer Production, Consumption, Import and Export 2020-2025

Table Global Monoclonal Antibodies for Non-small Cell Lung Cancer Historic Sales Revenue by Type in 2020-2025

Table Global Monoclonal Antibodies for Non-small Cell Lung Cancer Historic Sales Revenue Market Share by Type in 2020-2025

Table Global Monoclonal Antibodies for Non-small Cell Lung Cancer Forecasted Sales Revenue by Type in 2026-2031

Table Global Monoclonal Antibodies for Non-small Cell Lung Cancer Forecasted Sales Revenue Market Share by Type in 2026-2031

Table Global Monoclonal Antibodies for Non-small Cell Lung Cancer Historic Consumption Value by Application in 2020-2025

Table Global Monoclonal Antibodies for Non-small Cell Lung Cancer Historic

Cosumption Value Market Share by Application in 2020-2025

Table Global Monoclonal Antibodies for Non-small Cell Lung Cancer Forecasted

Cononumption Value by Application in 2026-2031

Table Global Monoclonal Antibodies for Non-small Cell Lung Cancer Forecasted

Cononumption Value Market Share by Application in 2026-2031

Table Roche Holding AG Monoclonal Antibodies for Non-small Cell Lung Cancer

Production Capacity, Revenue, Price and Gross Margin 2020-2025

Table Bristol Myers Squibb Co. Monoclonal Antibodies for Non-small Cell Lung Cancer

Production Capacity, Revenue, Price and Gross Margin 2020-2025

Table Elea Spa Monoclonal Antibodies for Non-small Cell Lung Cancer Production

Capacity, Revenue, Price and Gross Margin 2020-2025

Table Eli Lilly & Co. Monoclonal Antibodies for Non-small Cell Lung Cancer Production

Capacity, Revenue, Price and Gross Margin 2020-2025

Table Merck & Co., Inc. Monoclonal Antibodies for Non-small Cell Lung Cancer

Production Capacity, Revenue, Price and Gross Margin 2020-2025

Table AstraZeneca PLC Monoclonal Antibodies for Non-small Cell Lung Cancer

Production Capacity, Revenue, Price and Gross Margin 2020-2025

Table Regeneron Pharmaceuticals, Inc. Monoclonal Antibodies for Non-small Cell Lung

Cancer Production Capacity, Revenue, Price and Gross Margin 2020-2025

Table Henlius Biopharma Co., Ltd Monoclonal Antibodies for Non-small Cell Lung

Cancer Production Capacity, Revenue, Price and Gross Margin 2020-2025

Table Jiangsu Hengrui Medicine Co., Ltd Monoclonal Antibodies for Non-small Cell

Lung Cancer Production Capacity, Revenue, Price and Gross Margin 2020-2025

Table Innovent Biologics Co., Ltd Monoclonal Antibodies for Non-small Cell Lung

Cancer Production Capacity, Revenue, Price and Gross Margin 2020-2025

Table Junshi Biosciences Co., Ltd Monoclonal Antibodies for Non-small Cell Lung

Cancer Production Capacity, Revenue, Price and Gross Margin 2020-2025

Table BeiGene, Ltd Monoclonal Antibodies for Non-small Cell Lung Cancer Production

Capacity, Revenue, Price and Gross Margin 2020-2025

Table Akeso, Inc Monoclonal Antibodies for Non-small Cell Lung Cancer Production

Capacity, Revenue, Price and Gross Margin 2020-2025

Table Global Forecasted Production Volume of Monoclonal Antibodies for Non-small

Cell Lung Cancer by Region 2026-2031

Table Global Forecasted Sales Volume by Type in 2026-2031

Table Global Forecasted Sales Volume Market Share by Type in 2026-2031

Table Global Forecasted Sales Revenue by Type in 2026-2031

Table Global Forecasted Sales Revenue Market Share by Type in 2026-2031

Table Global Forecasted Sales Price by Type in 2026-2031

Table Global Forecasted Consumption Volume by Application in 2026-2031

Table Global Forecasted Consumption Value by Application in 2026-2031

Table Market Key Trends

Table Key Opportunities and Drivers: Impact Analysis 2026-2031

Table Key Challenges

Table Research Programs/Design for This Report

Table Key Data Information from Secondary Sources

Table Key Data Information from Primary Sources

List Of Figures

LIST OF FIGURES

Figure Global Market Share in Sales Revenue by Type in 2025

Figure 5 mg/mL Features

Figure 10 mg/mL Features

Figure 25 mg/mL Features

Figure 50 mg/mL Features

Figure Global Market Share in Consumption Value by Application in 2025

Figure Hospitals Case Studies

Figure Clinic Case Studies

Figure Others Case Studies

Figure Global Market Size in Sales Revenue Outlook 2026-2031

Figure North America Monoclonal Antibodies for Non-small Cell Lung Cancer Sales Revenue and Growth Rate 2026-2031

Figure East Asia Monoclonal Antibodies for Non-small Cell Lung Cancer Sales Revenue and Growth Rate 2026-2031

Figure Europe Monoclonal Antibodies for Non-small Cell Lung Cancer Sales Revenue and Growth Rate 2026-2031

Figure South Asia Monoclonal Antibodies for Non-small Cell Lung Cancer Sales Revenue and Growth Rate 2026-2031

Figure South America Monoclonal Antibodies for Non-small Cell Lung Cancer Sales Revenue and Growth Rate 2026-2031

Figure Middle East Monoclonal Antibodies for Non-small Cell Lung Cancer Sales Revenue and Growth Rate 2026-2031

Figure Africa Monoclonal Antibodies for Non-small Cell Lung Cancer Sales Revenue and Growth Rate 2026-2031

Figure Oceania Monoclonal Antibodies for Non-small Cell Lung Cancer Sales Revenue and Growth Rate 2026-2031

Figure South America Monoclonal Antibodies for Non-small Cell Lung Cancer Sales Revenue and Growth Rate 2026-2031

Figure Rest of the World Monoclonal Antibodies for Non-small Cell Lung Cancer Sales Revenue and Growth Rate 2026-2031

Figure Manufacturing Cost Structure Analysis of Monoclonal Antibodies for Non-small Cell Lung Cancer 2026

Figure Industry Chain Structure Analysis of Monoclonal Antibodies for Non-small Cell Lung Cancer 2026

Figure Global Monoclonal Antibodies for Non-small Cell Lung Cancer Production

Volume Market Share by Region in 2025

Figure Global Monoclonal Antibodies for Non-small Cell Lung Cancer Production

Revenue Market Share by Region in 2025

Figure North America Monoclonal Antibodies for Non-small Cell Lung Cancer

Production Volume Analysis 2020-2025

Figure North America Monoclonal Antibodies for Non-small Cell Lung Cancer

Production Revenue Analysis 2020-2025

Figure East Asia Monoclonal Antibodies for Non-small Cell Lung Cancer Production

Volume Analysis 2020-2025

Figure East Asia Monoclonal Antibodies for Non-small Cell Lung Cancer Production

Revenue Analysis 2020-2025

Figure Europe Monoclonal Antibodies for Non-small Cell Lung Cancer Production

Volume Analysis 2020-2025

Figure Europe Monoclonal Antibodies for Non-small Cell Lung Cancer Production

Revenue Analysis 2020-2025

Figure South Asia Monoclonal Antibodies for Non-small Cell Lung Cancer Production

Volume Analysis 2020-2025

Figure South Asia Monoclonal Antibodies for Non-small Cell Lung Cancer Production

Revenue Analysis 2020-2025

Figure Southeast Asia Monoclonal Antibodies for Non-small Cell Lung Cancer

Production Volume Analysis 2020-2025

Figure Southeast Asia Monoclonal Antibodies for Non-small Cell Lung Cancer

Production Revenue Analysis 2020-2025

Figure Middle East Monoclonal Antibodies for Non-small Cell Lung Cancer Production

Volume Analysis 2020-2025

Figure Middle East Monoclonal Antibodies for Non-small Cell Lung Cancer Production

Revenue Analysis 2020-2025

Figure Africa Monoclonal Antibodies for Non-small Cell Lung Cancer Production Volume

Analysis 2020-2025

Figure Africa Monoclonal Antibodies for Non-small Cell Lung Cancer Production

Revenue Analysis 2020-2025

Figure Oceania Monoclonal Antibodies for Non-small Cell Lung Cancer Production

Volume Analysis 2020-2025

Figure Oceania Monoclonal Antibodies for Non-small Cell Lung Cancer Production

Revenue Analysis 2020-2025

Figure South America Monoclonal Antibodies for Non-small Cell Lung Cancer

Production Volume Analysis 2020-2025

Figure South America Monoclonal Antibodies for Non-small Cell Lung Cancer

Production Revenue Analysis 2020-2025

Figure Roche Holding AG Monoclonal Antibodies for Non-small Cell Lung Cancer Product Specification

Figure Bristol Myers Squibb Co. Monoclonal Antibodies for Non-small Cell Lung Cancer Product Specification

Figure Elea Spa Monoclonal Antibodies for Non-small Cell Lung Cancer Product Specification

Figure Eli Lilly & Co. Monoclonal Antibodies for Non-small Cell Lung Cancer Product Specification

Figure Merck & Co., Inc. Monoclonal Antibodies for Non-small Cell Lung Cancer Product Specification

Figure AstraZeneca PLC Monoclonal Antibodies for Non-small Cell Lung Cancer Product Specification

Figure Regeneron Pharmaceuticals, Inc. Monoclonal Antibodies for Non-small Cell Lung Cancer Product Specification

Figure Henlius Biopharma Co., Ltd Monoclonal Antibodies for Non-small Cell Lung Cancer Product Specification

Figure Jiangsu Hengrui Medicine Co., Ltd Monoclonal Antibodies for Non-small Cell Lung Cancer Product Specification

Figure Innovent Biologics Co., Ltd Monoclonal Antibodies for Non-small Cell Lung Cancer Product Specification

Figure Junshi Biosciences Co., Ltd Monoclonal Antibodies for Non-small Cell Lung Cancer Product Specification

Figure BeiGene, Ltd Monoclonal Antibodies for Non-small Cell Lung Cancer Product Specification

Figure Akeso, Inc Monoclonal Antibodies for Non-small Cell Lung Cancer Product Specification

Figure Global Forecasted Production Capacity of Monoclonal Antibodies for Non-small Cell Lung Cancer 2026-2031

Figure Global Forecasted Production Revenue of Monoclonal Antibodies for Non-small Cell Lung Cancer 2026-2031

Figure North America Forecasted Production Capacity of Monoclonal Antibodies for Non-small Cell Lung Cancer 2026-2031

Figure North America Forecasted Production Revenue of Monoclonal Antibodies for Non-small Cell Lung Cancer 2026-2031

Figure East Asia Forecasted Production Capacity of Monoclonal Antibodies for Non-small Cell Lung Cancer 2026-2031

Figure East Asia Forecasted Production Revenue of Monoclonal Antibodies for Non-small Cell Lung Cancer 2026-2031

Figure Europe Forecasted Production Capacity of Monoclonal Antibodies for Non-small

Cell Lung Cancer 2026-2031

Figure Europe Forecasted Production Revenue of Monoclonal Antibodies for Non-small Cell Lung Cancer 2026-2031

Figure South Asia Forecasted Production Capacity of Monoclonal Antibodies for Non-small Cell Lung Cancer 2026-2031

Figure South Asia Forecasted Production Revenue of Monoclonal Antibodies for Non-small Cell Lung Cancer 2026-2031

Figure Southeast Asia Forecasted Production Capacity of Monoclonal Antibodies for Non-small Cell Lung Cancer 2026-2031

Figure Southeast Asia Forecasted Production Revenue of Monoclonal Antibodies for Non-small Cell Lung Cancer 2026-2031

Figure Middle East Forecasted Production Capacity of Monoclonal Antibodies for Non-small Cell Lung Cancer 2026-2031

Figure Middle East Forecasted Production Revenue of Monoclonal Antibodies for Non-small Cell Lung Cancer 2026-2031

Figure Africa Forecasted Production Capacity of Monoclonal Antibodies for Non-small Cell Lung Cancer 2026-2031

Figure Africa Forecasted Production Revenue of Monoclonal Antibodies for Non-small Cell Lung Cancer 2026-2031

Figure Oceania Forecasted Production Capacity of Monoclonal Antibodies for Non-small Cell Lung Cancer 2026-2031

Figure Oceania Forecasted Production Revenue of Monoclonal Antibodies for Non-small Cell Lung Cancer 2026-2031

Figure South America Forecasted Production Capacity of Monoclonal Antibodies for Non-small Cell Lung Cancer 2026-2031

Figure South America Forecasted Production Revenue of Monoclonal Antibodies for Non-small Cell Lung Cancer 2026-2031

Figure Rest of the World Forecasted Production Capacity of Monoclonal Antibodies for Non-small Cell Lung Cancer 2026-2031

Figure Rest of the World Forecasted Production Revenue of Monoclonal Antibodies for Non-small Cell Lung Cancer 2026-2031

Figure North America Forecasted Consumption of Monoclonal Antibodies for Non-small Cell Lung Cancer 2026-2031

Figure North America Forecasted Consumption of Monoclonal Antibodies for Non-small Cell Lung Cancer 2031 by Country

Figure East Asia Forecasted Consumption of Monoclonal Antibodies for Non-small Cell Lung Cancer 2026-2031

Figure East Asia Forecasted Consumption of Monoclonal Antibodies for Non-small Cell Lung Cancer 2031 by Country

Figure Europe Forecasted Consumption of Monoclonal Antibodies for Non-small Cell Lung Cancer 2026-2031

Figure Europe Forecasted Consumption of Monoclonal Antibodies for Non-small Cell Lung Cancer 2031 by Country

Figure South Asia Forecasted Consumption of Monoclonal Antibodies for Non-small Cell Lung Cancer 2026-2031

Figure South Asia Forecasted Consumption of Monoclonal Antibodies for Non-small Cell Lung Cancer 2031 by Country

Figure Southeast Asia Forecasted Consumption of Monoclonal Antibodies for Non-small Cell Lung Cancer 2026-2031

Figure Southeast Asia Forecasted Consumption of Monoclonal Antibodies for Non-small Cell Lung Cancer 2031 by Country

Figure Middle East Forecasted Consumption of Monoclonal Antibodies for Non-small Cell Lung Cancer 2026-2031

Figure Middle East Forecasted Consumption of Monoclonal Antibodies for Non-small Cell Lung Cancer 2031 by Country

Figure Africa Forecasted Consumption of Monoclonal Antibodies for Non-small Cell Lung Cancer 2026-2031

Figure Africa Forecasted Consumption of Monoclonal Antibodies for Non-small Cell Lung Cancer 2031 by Country

Figure Oceania Forecasted Consumption of Monoclonal Antibodies for Non-small Cell Lung Cancer 2026-2031

Figure Oceania Forecasted Consumption of Monoclonal Antibodies for Non-small Cell Lung Cancer 2031 by Country

Figure South America Forecasted Consumption of Monoclonal Antibodies for Non-small Cell Lung Cancer 2026-2031

Figure South America Forecasted Consumption of Monoclonal Antibodies for Non-small Cell Lung Cancer 2031 by Country

Figure Rest of the World Forecasted Consumption of Monoclonal Antibodies for Non-small Cell Lung Cancer 2026-2031

Figure Rest of the World Forecasted Consumption of Monoclonal Antibodies for Non-small Cell Lung Cancer 2031 by Country

Figure Channels of Distribution

Figure Porter's Five Forces Analysis

Figure Key Executives Interviewed

I would like to order

Product name: 2026-2031 Global Monoclonal Antibodies for Non-small Cell Lung Cancer Outlook Market Size, Share & Trends Analysis Report By Player, Type, Application and Region

Product link: <https://marketpublishers.com/r/M7D753AF3DC7EN.html>

Price: US\$ 3,150.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/M7D753AF3DC7EN.html>